Breaking Finance News

Cara Therapeutics (NASDAQ:CARA) stock price target increased to $20.00, reported today by H.C. Wainwright

Cara Therapeutics (NASDAQ:CARA) had its target price raised to $20.00 by H.C. Wainwright in a report released 10/13/2016. The new target price indicates a possible upside of 1.65% based on the company's last stock close price.

Previously on Monday August 08, 2016, Needham reported about Cara Therapeutics (NASDAQ:CARA) lowered the target price from $27.00 to $23.00. At the time, this indicated a possible upside of 2.92%.

Yesterday Cara Therapeutics (NASDAQ:CARA) traded -7.35% lower at $7.56. The company’s 50-day moving average is $6.99 and its 200-day moving average is $6.18. The last stock close price is up 22.31% from the 200-day moving average, compared to the S&P 500 which has decreased -0.01% over the same time. 1,525,193 shares of the stock exchanged hands, up from an avg. volume of 990,751

Recent Performance Chart

Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics has with a one year low of $4.26 and a one year high of $18.12 and has a market capitalization of $0.

General Company Details For Cara Therapeutics (NASDAQ:CARA)

Cara Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing and commercializing chemical entities designed to alleviate pain and pruritus by focusing on kappa opioid receptors. The Company is engaged in developing product candidates that focus on the body's peripheral nervous system. Its product candidate pipeline includes I.V. CR845 for acute pain; I.V. CR845 for uremic pruritus; Oral CR845, and CR701. The Company's I.V. CR845 is an injectable version of peripheral kappa opioid receptor agonist, which is intended for the treatment of acute pain in an acute care setting. The Company is developing an oral version of CR845 for the treatment of moderate-to-severe acute and chronic pain. The Company's CR701 is a peripherally-restricted, mixed-CB1/CB2 receptor agonist that interacts with cannabinoid receptor subtypes, with no off-target activities. CR701 is in preclinical-stage of development.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.